Private Management Group Inc. Trims Stock Holdings in Elanco Animal Health Incorporated $ELAN

Private Management Group Inc. reduced its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 20.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,281,074 shares of the company’s stock after selling 328,696 shares during the quarter. Private Management Group Inc.’s holdings in Elanco Animal Health were worth $28,991,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ELAN. Root Financial Partners LLC increased its stake in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares during the last quarter. Huntington National Bank grew its stake in shares of Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares in the last quarter. Torren Management LLC acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at about $46,000. Fifth Third Bancorp grew its stake in shares of Elanco Animal Health by 3,018.3% in the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after buying an additional 2,807 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Elanco Animal Health by 43.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock valued at $70,000 after buying an additional 938 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of recent analyst reports. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Morgan Stanley raised their price target on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. raised their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Citigroup raised their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.20.

Insider Buying and Selling at Elanco Animal Health

In other news, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction dated Friday, May 15th. The shares were bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Stock Up 5.4%

ELAN opened at $24.10 on Friday. Elanco Animal Health Incorporated has a 12 month low of $13.15 and a 12 month high of $27.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The stock has a market cap of $12.04 billion, a P/E ratio of -48.20, a P/E/G ratio of 1.50 and a beta of 1.69. The stock’s 50 day moving average price is $22.88 and its 200 day moving average price is $23.47.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same period last year, the firm earned $0.37 EPS. The firm’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.